**INVESTIGATIVE REPORT**

**Iodine and Gliadin Challenge on Oral Mucosa in Dermatitis Herpetiformis**

P. Patinen1,2, J. Hietanen1,3, M. Malmström1, T. Reunala4 and E. Savilahti4

1Departments of Oral Surgery, Pathology and Medicine, Institute of Dentistry, University of Helsinki, 2Department of Oral and Maxillofacial Surgery, Department of Surgery, 3Oral Pathology Unit, Laboratory Diagnostics and 4Children’s Hospital, Helsinki University Central Hospital, Helsinki, 5Departments of Dermatology, University Hospitals and Universities of Helsinki and Tampere, Finland

Oral lesions and mucosal inflammatory changes may appear in dermatitis herpetiformis (DH). We examined whether potassium iodine, known to initiate blisters in the DH skin, or wheat gliadin, responsible for T-cell-dependent intestinal damage, can induce visible or microscopic changes in oral mucosa. Six patients with active DH were challenged with crude gliadin and 50% potassium iodine applied in patch test chambers on buccal mucosa for 12 h. After reading, biopsies were taken from the challenged and non-challenged mucosa. No macroscopic or microscopic vesicles were seen. However, gliadin-but not iodine-challenged epithelium showed increased numbers of CD4+ lymphocytes in all 5 patients with representative specimens (p = 0.06). No marked changes were found in the numbers of CD8+ or TcR α/β+ lymphocytes, and the numbers of TcR γ/δ+ cells remained at a low level. The results show that oral mucosa is resistant to production of macroscopic or microscopic DH lesions. It is, however, capable of reacting to locally applied gliadin by a T-cell response consisting of CD4+ lymphocytes. 

**Key words: coeliac disease; dermatitis herpetiformis; gluten; iodine; oral mucosa; T lymphocytes.**

(Accepted January 3, 2002.)


Timo Reunala, Department of Dermatology, Tampere University Hospital, P.O. Box 2000, FIN-33521 Tampere, Finland. E-mail: timo.reunala@tays.fi

Dermatitis herpetiformis (DH) is a gluten-sensitive, blistering skin disease with pathognomonic IgA deposits in the skin and oral mucosa (1, 2). Blisters may also occur in the oral cavity (3), and a recent study reported that mucosal ulceration and lymphocytic inflammation is a common finding in DH (4). The rash and damage in small bowel in DH respond to gluten withdrawal, but the effect of the diet on various oral lesions is not known. At present, it seems evident that a T-cell-mediated immune response against gliadin, a component of wheat gluten, is involved in the production of the gut lesion (5). Epithelial γ/δ T-cell receptor bearing lymphocytes (TcR) are typical of the inflamed intestineum (6), but these cells seem not to be present in DH skin (7, 8).

In the present study in DH, we examined how sensitive oral mucosa is to blister formation by challenging it with potassium iodine, an agent known to initiate blistering in DH skin (9). An additional challenge was performed with gliadin to study whether oral mucosa is capable of reacting against this antigen by a T-cell response.

**MATERIAL AND METHODS**

**Patients**

Six patients with DH (5 men, 1 woman, aged 35–75 years) volunteered for the study. The diagnosis of DH was based on demonstration of granular IgA deposits in the unaffected skin. Small-bowel biopsy showed subtotal or partial villous atrophy in 5 and inflammatory changes in one patient. At the time of the study, all patients used dapsone (25–75 mg/day) to control the rash. Three newly diagnosed patients were on a normal gluten-containing diet and 3 had tried for several months to adhere to a gluten-free diet, but had all consumed some gluten, at least weekly. Five of the patients had increased IgA class antigliadin antibody levels in ELISA and 4 showed IgA endomysium antibodies (titer 10–1600) in the serum (10). Dapsone was withdrawn 48 h before the study and after it all patients showed active skin lesions. Two healthy volunteers (age 37 and 42 years) served as controls in oral challenge. The study was approved by the Ethics Committee of Helsinki University Hospital for Skin and Allergic Diseases.

**Challenges and immunohistochemistry**

Fifty percent potassium iodine in petrolatum and gliadin powder (30 mg; Sigma Chemicals, St. Louis, MO, USA) moistened with but not diluted in physiological saline was applied in 8 mm diameter aluminum patch test chambers (Finnchamber, Epicon Ltd, Tuusula, Finland). These were fixed with occlusive bandage (Stomahesive®, Squibb, Princeton, NJ, USA) on buccal mucosa of the molar area just below linea alba. The chambers were removed after 12 h and 4 mm punch biopsies were taken from the challenged and non-challenged (control) mucosa under 2% lidocaine with adrenaline. The biopsy specimens were snap-frozen in liquid nitrogen, embedded in a mounting media (OCT, Tissue Tek; Miles, Elkhart, IN, USA) and the staining was performed with the avidin-biotin peroxidase method as previously described (6, 10). Monoclonal antibodies used were OKT8 (dilution 1:20; Becton Dickinson, Mountain View, CA, USA) for CD8+ cells, T4 (dilution 1:20; Coulter Immunology, Hialeah, FL, USA) for CD4+ cells, TCRd1 (dilution 1:200; T cell Sciences, Cambridge, MA, USA) for TcR gamma/delta+ cells and BF1 (dilution 1:100; T cell Sciences) for TcR alpha/beta+ cells. Counterstaining was performed with haematoxylin. Positively
stained T cells were counted in the epithelium and lamina propria with a light microscope through a calibrated graticule at 400 × magnification, as previously described (11). The results were given as cells/mm².

Statistics
The permutation test for paired replicates was used to compare the cell counts in the challenged and control mucosa (12). A p-value below 0.05 was considered significant.

RESULTS

Clinical and histological findings
Though all 6 patients with DH had active lesions in the skin at the end of the 12-h oral challenge, none of them showed any blisters or clinically evident inflammatory changes on the potassium-iodine- or gliadin-challenged buccal mucosa. In agreement with this, none of the biopsy specimens from the challenge sites showed subepithelial vesicles or polymorphonuclear leukocyte microabscesses typical of DH lesions. The oral mucosa of the 2 gliadin and potassium-iodine-challenged control persons remained also clinically and histologically negative.

T-cell response
In the epithelium, all 5 patients with representative biopsy specimens showed increased numbers of CD4+ T lymphocytes compared to the control sites in the gliadin challenge sites (Fig. 1). This increase was almost significant (p = 0.06). In contrast to gliadin, potassium iodine did not cause any marked influx of CD4+ lymphocytes into the epithelium (Fig. 1). The alpha/beta TcR+ cells did not show any statistically significant change either in the gliadin or in the potassium iodine challenge sites because individual variation was large (Fig. 1). Similarly, no significant change were found in the numbers of CD8+ cells in the gliadin (median 111 cells/mm²; percentiles 75 and 154 cells/mm²) or potassium iodine (106; 81 and 184 cells/mm²) challenge sites compared to the control sites (45; 31 and 114 cells/mm²; p = 0.12 and 0.44).

In the lamina propria, the numbers of CD4+ cells in the gliadin (109; 103 and 156 cells/mm²) or potassium iodine (47; 23 and 72 cells/mm²) challenge sites did not show any marked increase compared to control sites (28; 15 and 58 cells/mm²; p = 0.12). Similarly, the numbers of TeR alpha/beta + cells were unaltered in the gliadin (57; 37 and 72/cells/mm²) and potassium iodine (107; 36 and 144 cells/mm²) challenge sites compared to the control sites (62; 47 and 87 cells/mm²; p = 0.03 and 0.37).

In contrast to alpha/beta TcR+ cells, only very few gamma/delta TcR+ cells were seen intraepithelially or in lamina propria in the gliadin- or potassium-iodine-challenged sites (maximum 5 cells/mm²) in the control sites, so no statistical comparisons could be performed.

DISCUSSION
It is generally believed that DH rarely affects the oral cavity, though pathognomonic IgA deposits occur frequently in the oral mucosa (1, 2). In an earlier DH study, however, oral lesions were found in more than 70% of patients and a recent study reported unspecified mucosal ulceration in 37% of patients compared to none of the controls (3, 4). In the present study we examined 6 patients with active DH in the skin and exposed their normal-appearing oral mucosa to 50% potassium iodine. We observed no visible or microscopic lesions in the oral mucosa, though in the previous studies skin challenge with potassium iodine has brought lesions to most patients with active DH (9, 13). We conclude, therefore, that at least in experimental conditions oral mucosa is not as sensitive as the skin for development of DH lesions. One possible reason for the different responses could be that the oral epithelial cells do not respond to an inflammatory agent, i.e. potassium iodine, in a similar way to the keratinocytes in the skin by showing early upregulation of urokinase plasminogen activator with subsequent activation of macrophage matrix metalloproteinase (13, 14).

In the present study we also examined whether gliadin challenge on oral mucosa could produce oral lesions or influx of immunocompetent cells. No visible or microscopic blisters were seen, but gliadin challenge caused a marked influx of CD4+ lymphocytes in the epithelium in all 5 patients with representative specimens (Fig. 2). This increase was statistically almost significant (p = 0.06). In contrast to CD4+ lymphocytes, the numbers...
of CD8+ and alpha/beta TcR+ cells remained unaltered in the epithelium. These findings are in good agreement with those observed recently by Lähteenoja et al. in patients with coeliac disease (15, 16). They applied gliadin powder on oral mucosa with the aid of an adhesive bandage for 6–24 h and found a similar increase of the CD4+ cells in the epithelium as we did. These results show that, at least under occlusion, gliadin, which is fairly insoluble in water, can penetrate mucosa and cause an influx of immunocompetent cells. Supporting this, Lähteenoja et al. (15, 16) could also document an influx of the TcR alpha/beta+ cells and increased expression of IL-2 receptor on T cells with submucosally injected gliadin or gliadin peptides. Moreover, the present study in DH and the previous study in coeliac disease by Lähteenoja et al. (15) documented that mucosal gliadin challenge did not cause any influx of TcR gamma/delta+ cells into the epithelium, indicating that a marked difference exists between the occurrence of these cells in the oral and gut mucosa (6, 11, 18).

The present and previous results in the patients with DH and coeliac disease indicate that application of gliadin on oral mucosa is capable of causing a prominent CD4+ influx into the epithelium and that submucosal injection of gliadin causes TcR alpha/beta + cell influx and general T-cell activation. Further studies are needed to show the specificity and cytokine pattern of the orally invading T cells, because gliadin-specific T cells are known to occur in coeliac intestine (18, 19) though not in the DH skin (20, 21).

In conclusion, the present study showed that DH lesions are not easy to produce on oral mucosa. It also documented that in DH, as in coeliac disease, mucosal gliadin challenge can evoke a CD4+ lymphocyte but not TcR gamma/delta+ cell influx into the oral epithelium.

ACKNOWLEDGEMENTS

We thank Hanu Kautiainen, MA, for performing statistical analyses. The skilful technical assistance of Ms Sirkku Kristiansen and Mrs Marjatta Kivekäs is greatly acknowledged. The study was supported by a grant from the Finnish Dental Society.

REFERENCES

17. Maiuri L, Pickarelli A, Boirivant M, Coletta S, Mazzirilli...


